Most Second-Line Lymphoma Patients Miss Curative Therapy

Company LEO Consortium (Lymphoma Epidemiology of Outcomes) Event Type Peer-Reviewed Publication (Real-World Cohort Study) Platform Autologous Stem-Cell Transplantation / CD19-Directed CAR-T Indication Relapsed or Refractory Large B-Cell Lymphoma Summary The LEO CReWE study analyzed 1,504 patients with relapsed or refractory large B-cell lymphoma treated from…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Weekly Market Insight

Terremoto – $108M Series C Degrader Platform
Nurix–Roche BTK Degrader Deal Closes
Lilly + Ascidian – $1.9B RNA Exon Editing Deal
MeiraGTx – $400M Oberland Strategic Financing for Late-Stage Gene Therapy Programs